Search Result

Results for "

Lewy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Biochemical Assay Reagents (1) Endogenous Metabolite (9) Epoxide Hydrolase (1) FBPase (3) Fluorescent Dye (1) Histone Demethylase (1) iGluR (2) Mitochondrial Metabolism (1) Monoamine Oxidase (1) nAChR (1) Phosphodiesterase (PDE) (3) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Tyrosine Hydroxylase (1) α-synuclein (11)
By Research Areas:	Cancer (3) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (29)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113407A

D-Fructose-6-phosphate disodium	Endogenous Metabolite FBPase	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate disodium is an endogenous metabolite. D-Fructose 6-phosphate disodium can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate disodium can be used to study Lewy body dementia .

HY-113228

Isocitric acid 2 Publications Verification	Endogenous Metabolite	Neurological Disease
Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia .

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-132821

Irsenontrine E2027	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases .

HY-N0698

Crocin II	Endogenous Metabolite α-synuclein	Neurological Disease Cancer
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease .

HY-113407

D-Fructose-6-phosphate	Endogenous Metabolite FBPase	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate is an endogenous metabolite. D-Fructose 6-phosphate can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate can be used to study Lewy body dementia .

HY-113228R

Isocitric acid (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease
Isocitric acid (Standard) is the analytical standard of Isocitric acid (HY-113228). This product is intended for research and analytical applications. Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia.

HY-125287

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-132821B

(R)-Irsenontrine (R)-E2027	Phosphodiesterase (PDE)	Neurological Disease
(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC₅₀ value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases .

HY-178920

α-Synuclein-IN-17	α-synuclein	Neurological Disease
α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC₅₀ value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-156634

Risevistinel NYX-783	iGluR	Neurological Disease
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-175308

α-Synuclein inhibitor 15	α-synuclein	Neurological Disease
α-Synuclein inhibitor 15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC₅₀=18 μM). α-Synuclein inhibitor 15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD) .

HY-156626

Nevadistinel NYX-458; NYX-3054	iGluR	Neurological Disease
Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-132821A

Irsenontrine maleate E2027 maleate	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases .

HY-135653A

(Rac)-EC5026 (Rac)-BPN-19186	Epoxide Hydrolase	Neurological Disease
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a K_i of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .

HY-108227

Quetiapine sulfone	5-HT Receptor	Neurological Disease
Quetiapine sulfone is a main metabolite of Quetiapine (HY-14544). Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist .

HY-153127

Florbenazine AV-133	Biochemical Assay Reagents	Neurological Disease
Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter VMAT2, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease) .

HY-W725496

D-Fructose 6-phosphate dipotassium	Endogenous Metabolite	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

HY-N0698R

Crocin II (Standard)	Reference Standards Endogenous Metabolite α-synuclein	Neurological Disease Cancer
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

HY-156600A

Bevemipretide trihydrochloride SBT-272 trihydrochloride	Mitochondrial Metabolism	Neurological Disease
Bevemipretide trihydrochloride (SBT-272 trihydrochloride) is a blood-brain barrier-permeable mitochondrial function repair agent. Bevemipretide trihydrochloride stabilizes cardiolipin in the inner mitochondrial membrane, restores mitochondrial structure, respiratory function, motor capacity and upper motor neuron health. Bevemipretide trihydrochloride reduces astrogliosis and microgliosis in mice with amyotrophic lateral sclerosis. Bevemipretide trihydrochloride prevents stroke-induced mitochondrial dysfunction . Bevemipretide trihydrochloride is applicable to research related to amyotrophic lateral sclerosis, Parkinson's disease, dementia with Lewy bodies and Huntington's disease .

HY-113407B

D-Fructose-6-phosphate disodium hydrate	Endogenous Metabolite FBPase	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate disodium hydrate is an endogenous metabolite. D-Fructose 6-phosphate disodium hydrate can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium hydrate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium hydrate can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate disodium hydrate can be used to study Lewy body dementia .

HY-125984

Syn-516	α-synuclein	Neurological Disease
Syn-516 is an inhibitor of α-synuclein (α-Syn). Syn-516 targets the 5' untranslated region (5'UTR) of α-Syn mRNA, with an IC₅₀ value of 1.8 μM, thereby inhibiting the translation process of α-Syn. Syn-516 improves motor dysfunction and colonic motility abnormalities associated with α-Syn overexpression in mouse models. α-Syn can be used to study diseases such as Parkinson's disease and Lewy body dementia .

HY-182893

SK-129	α-synuclein Reactive Oxygen Species (ROS) Tyrosine Hydroxylase	Neurological Disease
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a K_d of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .

HY-W777920

C26-Dihydro ceramide	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
C26-Dihydro ceramide is a dihydroceramide containing a C26 very-long-chain fatty acid. C26-Dihydro ceramide can be used for research on various neurological disorders including Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, and anxiety disorders .

HY-136878

LSD1-IN-10	Histone Demethylase Monoamine Oxidase	Neurological Disease Cancer
LSD1-IN-10 is a LSD1/MAO inhibitor with LSD1 IC₅₀ of 5 nM, MAO-A IC₅₀ of 16 μM, and MAO-B IC₅₀ of 7.4 μM. LSD1-IN-10 suppresses enzymatic activity of LSD1, MAO-A, and MAO-B. LSD1-IN-10 can be used for the research of cancer, alzheimer's disease, parkinson's disease, huntington's disease .

Cat. No.	Product Name	Type

HY-W725496

D-Fructose 6-phosphate dipotassium	Biochemical Assay Reagents
D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

D-Fructose 6-phosphate dipotassium

Biochemical Assay Reagents

D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

Cat. No.	Product Name	Target	Research Area

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

D-Fructose-6-phosphate disodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite FBPase
D-Fructose 6-phosphate disodium is an endogenous metabolite. D-Fructose 6-phosphate disodium can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate disodium can be used to study Lewy body dementia .

Crocin II	Structural Classification Neurological Disease Classification of Application Fields Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite α-synuclein
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

Peucedanocoumarin III	Structural Classification Carpesium cernuum L. Coumarins Phenylpropanoids Umbelliferae Plants Source Classification	α-synuclein
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease .

D-Fructose-6-phosphate	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite FBPase
D-Fructose 6-phosphate is an endogenous metabolite. D-Fructose 6-phosphate can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate can be used to study Lewy body dementia .

Isocitric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Isocitric acid (Standard) is the analytical standard of Isocitric acid (HY-113228). This product is intended for research and analytical applications. Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia.

Crocin II (Standard)	Structural Classification Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Source Classification	Reference Standards Endogenous Metabolite α-synuclein
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

Host:	Mouse (2) Rabbit (1)
Reactivity:	Human (3) Mouse (1) Rat (1)
Application:	IHC-P (2) IF-Tissue (2) IHC-F (2) WB (3)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86701

	alpha Synuclein Antibody (YA6393) SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); Synuclein alpha; Synuclein, alpha(non A4 component of amyloid precursor); Synuclein-α; Synuclein α.	WB	Rat, Mouse, Human
	alpha Synuclein Antibody (YA6393) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P86749

	alpha Synuclein Antibody (YA6441) SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); Synuclein alpha; Synuclein, alpha(non A4 component of amyloid precursor); Synuclein-α; Synuclein α.	WB, IHC-P, IHC-F, IF-Tissue	Human
	alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P86749A

	alpha Synuclein Antibody (YA6441)(PBS only) SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); Synuclein alpha; Synuclein, alpha(non A4 component of amyloid precursor); Synuclein-α; Synuclein α.	WB, IHC-P, IHC-F, IF-Tissue	Human
	alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Lewy

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Antibodies

Natural
Products